Literature DB >> 7619986

Long-term sequelae of Rocky Mountain spotted fever.

L K Archibald1, D J Sexton.   

Abstract

Twenty-five patients with definite or probable Rocky Mountain spotted fever (RMSF) who were hospitalized for > or = 2 weeks were identified from our database of 105 patients. Follow-up information was collected for 20 patients, per telephone and/or medical records. The remaining five patients were lost to follow-up or died. Nine patients had > or = 1 long-term sequelae (defined as complications related to an original acute infection with Rickettsia rickettsii that persisted for > or = 1 year following hospital discharge). The ages of patients with sequelae ranged from 2 to 74 years (mean and median, 38 years); duration of follow-up ranged from 1 to 18 years (mean, 11 years). The mean lengths of hospitalization for patients with and without long-term sequelae were 47 days and 20 days, respectively (P < .05). Long-term neurological sequelae included paraparesis; hearing loss; peripheral neuropathy; bladder and bowel incontinence; cerebellar, vestibular, and motor dysfunction; and language disorders. Nonneurological sequelae consisted of disability from limb amputation and scrotal pain following cutaneous necrosis. These data suggest that significant long-term morbidity is common in patients with severe illness due to RMSF.

Entities:  

Mesh:

Year:  1995        PMID: 7619986     DOI: 10.1093/clinids/20.5.1122

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Clinical manifestations of tick-borne infections in children.

Authors:  K A Bryant; G S Marshall
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

Review 2.  The Rickettsioses: A Practical Update.

Authors:  Lucas S Blanton
Journal:  Infect Dis Clin North Am       Date:  2019-03       Impact factor: 5.982

3.  Coinfection with multiple tick-borne pathogens in a Walker Hound kennel in North Carolina.

Authors:  S K Kordick; E B Breitschwerdt; B C Hegarty; K L Southwick; C M Colitz; S I Hancock; J M Bradley; R Rumbough; J T Mcpherson; J N MacCormack
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

4.  Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs.

Authors:  E B Breitschwerdt; M G Papich; B C Hegarty; B Gilger; S I Hancock; M G Davidson
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 5.  Rickettsioses as paradigms of new or emerging infectious diseases.

Authors:  D Raoult; V Roux
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

6.  Incidence Rate of Somatic Dysfunction in Previously Undiagnosed Spotted Fever Rickettsiosis: A Case Report.

Authors:  Mark D Unger; Joy L Palmer; Nichole M Thorsvik
Journal:  Cureus       Date:  2022-04-23

Review 7.  Rickettsial infections of the central nervous system.

Authors:  Zuzana Sekeyová; Monika Danchenko; Peter Filipčík; Pierre Edouard Fournier
Journal:  PLoS Negl Trop Dis       Date:  2019-08-29

8.  Modeling of Control Efforts against Rhipicephalus sanguineus, the Vector of Rocky Mountain Spotted Fever in Sonora Mexico.

Authors:  Gerardo Alvarez-Hernandez; Alejandro Villegas Trejo; Vardayani Ratti; Michael Teglas; Dorothy I Wallace
Journal:  Insects       Date:  2022-03-07       Impact factor: 2.769

9.  Long term neurologic sequelae in a Mexican rocky mountain spotted fever case.

Authors:  Karla Rossanet Dzul-Rosado; Cesar Lugo-Caballero; Alejandra Salcedo-Parra; Raymundo Daniel López-Soto; Álvaro A Faccini-Martínez
Journal:  Braz J Infect Dis       Date:  2019-05-16       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.